2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.
Yousef Zakharia, MD, medical oncologist, associate professor of medicine, the University of Iowa, the University of Iowa Hospitals and Clinics, discusses the real-world treatment outcomes of first-line axitinib (Inlyta) plus pembrolizumab (Keytruda) in patients with advanced renal cell carcinoma (RCC) based on International Metastatic RCC Database Consortium (IMDC) risk score.
Related Content: